Madam Therapeutics closes first financing round to develop novel antibiotics against drug resistant bacteria
Madam Therapeutics, a privately-held biotech company that is developing a novel class of antibiotics inspired by the defense mechanisms of the human body, today announced the closing of its first financing round of 1,1M EUR.
On the 22nd of May, alongside the annual World Health Assembly in Geneva the Global Antimicrobial Resistance and Development Hub (Global AMR R&D Hub) was launched.
Millions earmarked to boost research into new life-saving products to address the global rise of drug-resistant bacteria
The UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.
NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated the column “Company in the spotlight” issue. In our second edition, we speak with Dr. Hans Platteeuw, founder and CEO of Avivia B.V., a Nijmegen based company that supports pharmaceutical development for new and existing drugs including drug repurposing and reformulation.
Dutch researchers report on novel antimicrobial peptide to combat drug-resistant bacteria and biofilms
Researchers from the Leiden University Medical Center (LUMC), Academic Medical Center (AMC) and the Association of Dutch Burn Centers have published on the use of antimicrobial peptide SAAP-148 to combat drug-resistant bacteria and biofilms in the latest edition of the scientific journal Science Translational Medicine.
The Belgian Health Care Knowledge Centre (KCE) and ZonMw, the Netherlands Organisation for Health Research and Care innovation, invest a maximum of 6 million euros in a joint programme under the name ‘BeNeFIT’.